Biopolym. Cell. 2022; 38(3):195-204.
Bioorganic Chemistry
Study in vitro of the anticancer activity of [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide toward human tumor cells
1Finiuk N. S., 2Drapak I. V., 2Zimenkovsky B. S., 1Stoika R. S.
  1. Institute of Cell Biology, NAS of Ukraine
    14/16, Drahomanov Str., Lviv, Ukraine, 79005
  2. Danylo Halytsky Lviv National Medical University
    69, Pekarska Str., Lviv, Ukraine, 79010


Aim. In vitro study and characterization of anticancer activity of heterocyclic derivative — [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide. Methods. The cell culture; MTT assay. Results. We synthesized [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide, which possessed the cardioprotective, as well as the hypolipidemic, anti-inflammatory, analgesic, antihypertensive and antioxidant effects. Here, we investigated its growth inhibitory action towards tumor cell lines of various tissue origins: leukemia (HL-60, Jurkat), liver (HepG2), breast (MCF-7), lung (A549), cervical (KB3-1) and glioma (U251, U373, T98G) cells. We found that the leukemia cells were the most sensitive to the action of [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide with a mean of IC50 values at 7.5–8.9 μg/mL. Conclusions. The anti-proliferative activity of [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide dropped in the order: leukemia > hepatocarcinoma ~ cervix > lung carcinoma > glioblastoma > breast carcinoma cells. Thus, we revealed in one molecule of ([3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide) a combination of both the cardioprotective and anticancer activities that is of great significance for this agent as a potent anticancer medicine.
Keywords: [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide, cytotoxicity in vitro, anticancer activity


[1] Seitz J, Vineberg JG, Zuniga ES, Ojima I. Fluorine-containing taxoid anticancer agents and their tumor-targeted drug delivery. J Fluor Chem. 2013; 152:157-65.
[2] de Siqueira LRP, de Moraes Gomes PAT, de Lima Ferreira LP, de Melo Rêgo MJB, Leite ACL. Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues. Eur J Med Chem. 2019; 170:237-60.
[3] Anuradha, Patel S, Patle R, Parameswaran P, Jain A, Shard A. Design, computational studies, synthesis and biological evaluation of thiazole-based molecules as anticancer agents. Eur J Pharm Sci. 2019; 134:20-30.
[4] Zhang J, Wang S, Ba Y, Xu Z. Tetrazole hybrids with potential anticancer activity. Eur J Med Chem. 2019; 178:341-51.
[5] Alrohily WD, Habib ME, El-Messery SM, Alqurshi A, El-Sabagh H, Habib EE. Antibacterial, antibiofilm and molecular modeling study of some antitumor thiazole based chalcones as a new class of DHFR inhibitors. Microb Pathog. 2019; 136:103674.
[6] Bharti SK, Nath G, Tilak R, Singh SK. Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2, 4-disubstituted thiazole ring. Eur J Med Chem. 2010; 45(2):651-60.
[7] Xu Z, Ba M, Zhou H, Cao Y, Tang C, Yang Y. European 2,4,5-trisubstituted thiazole derivatives: A novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase. Eur J Med Chem. 2014; 85:27-42.
[8] Giri RS, Thaker HM, Giordano T, Williams J, Rogers D, Sudersanam V, Vasu KK. Design, synthesis and charac-terization of novel 2-(2,4-disubstituted-thiazole-5-yl)-3-aryl-3H-quinazoline-4-one derivatives as inhibitors of NF-kappaB and AP-1 mediated transcription activation and as potential anti-inflammatory agents. Eur J Med Chem. 2009; 44(5):2184-89.
[9] Shiradkar M, Suresh Kumar GV, Dasari V, Tatikonda S, Akula KC, Shah R. Clubbed triazoles: a novel approach to antitubercular drugs. Eur J Med Chem. 2007; 42(6):807-16.
[10] Rouf A, Tanyeli C. Bioactive thiazole and benzothiazole derivatives. Eur J Med Chem. 2015; 97:911-27.
[11] Turan-Zitouni G, Altıntop MD, Özdemir A, Kaplancıklı ZA, Çiftçi GA, Temel HE. Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents. Eur J Med Chem. 2016; 107:288-94.
[12] Wang Y, Wu C, Zhang Q, Shan Y, Gu W, Wang S. Design, synthesis and biological evaluation of novel β-pinene-based thiazole derivatives as potential anticancer agents via mitochondrial-mediated apoptosis pathway. Bioorg Chem. 2019; 84:468-77.
[13] Afifi OS, Shaaban OG, Abd El Razik HA, Shams El-Dine SEA, Ashour FA, El-Tombary AA, Abu-Serie MM. Syn-thesis and biological evaluation of purine-pyrazole hybrids incorporating thiazole, thiazolidinone or rhodanine moiety as 15-LOX inhibitors endowed with anticancer and antioxidant potential. Bioorg Chem. 2019; 87:821-37.
[14] Das D, Sikdar P, Bairagi M. Recent developments of 2-aminothiazoles in medicinal chemistry. Eur J Med Chem. 2016; 109:89-98.
[15] Xu Q, Dai B, Li Z, Xu L, Yang D, Gong P, Hou Y, Liu Y. Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia. Bioorg Med Chem Lett. 2019 29(19):126630.
[16] Haoran Y, Qianqian L, Xiaodong G, Yujie R, Yonghong G. Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: design, synthesis and anticoagulant activity evaluation. Eur J Med Chem. 2017; 126:799-809.
[17] Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, Han X, Macci R, Mathias NR, Moench P, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Macor JE, Dubowchik GM. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human cal-citonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem. 2008; 51(16):4858-61.
[18] Koppireddi S, Chilaka DR, Avula S, Komsani JR, Kotamraju S, Yadla R. Synthesis and anticancer evaluation of 3-aryl-6-phenylimidazo [2,1-b]thiazoles. Bioorg Med Chem Lett. 2014; 24(23):5428-31.
[19] Ghorab MM, Alsaid MS, El-Gaby MSA, Elaasser MM, Nissan YM. Antimicrobial and anticancer activity of some novel fluorinated thiourea derivatives carrying sulfonamide moieties: synthesis, biological evaluation and molecular docking. Chem Cent J. 2017; 11(1):32.
[20] Carrasco R, Ramirez MC, Nes K, Schuster A, Aguayo R, Morales M, Ramos C, Hasson D, Sotomayor CG, He-nriquez P, Cortés I, Erazo M, Salas C, Gormaz JG. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial). Trials. 2020; 21(1): 137.
[21] Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess. 2007; 11(27):iii, ix-x, 1-84.
[22] Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med. 2016; 31(4):625-33.
[23] Koppireddi S, Chilaka DR, Avula S, Komsani JR, Kotamraju S, Yadla R. Synthesis and anticancer evaluation of 3-aryl-6-phenylimidazo [2,1-b]thiazoles. Bioorg Med Chem Lett. 2014; 24(23):5428-31.
[24] Drapak I, Zimenkovsky B, Seredynska N, Perekhoda L, Demchenko A, Holota S, Nektegaev I [3-Allyl-4-(41-methoxyphenyl)-3H-thiazol-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide (Cardia-zole), which exhibits cardioprotective and antioxidant activity. Patent UA N140537; 22.07.2019; 10.03.2020, 5.
[25] Perekhoda LO, Drapak IV, Suleiman MM, Sych IA, Yaremenko VD. Synthesis and in silico research of derivatives of 3-allyl-4-(R-phenyl)-N-(R1-phenyl)thiazole-2-imine.Der Pharma Chemica. 2017;9(13):95-8.
[26] Yeromina HO, Drapak IV, Perekhoda LO, Yaremenko VD, Demchenko AM. Synthesis of 2-(4-aryl(adamantyl)-2-phenyliminothiazol-3-yl)-ethanol derivatives and prediction of their biological activity. Der Pharma Chemica. 2016; 8(3):64-70.
[27] Drapak I, Zimenkovsky B, Perekhoda L, Kovalenko S, Logoyda L. LC-MS/MS method development and valida-tion for the determination of cardiazol in human plasma. Int J App Pharm. 2019; 11(4):380-85.
[28] Drapak I, Perekhoda L, Demchenko N, Suleiman M, Rakhimova M, Demchuk I, Taran S, Seredynska N, Gerash-chenko I. Cardioprotective activity of some 2-arylimino-1,3-thiazole derivatives. Sci Pharm. 2019; 87(1):7.
[29] Drapak I, Zimenkovsky B, Perekhoda L, Yeromina H, Lipakova K, Demchuk I, Rakhimova M. QSAR-analysis of 1-[2-(R-phenylimino)-4-methyl-3-(3-[morpholine-4-yl]propyl)-2,3-dihydro-1,3-thiazol-5-yl]ethane-1-ones deriv-atives as potential antioxidants. Pharmacia. 2019; 66(1):33-40.
[30] Drapak I, Suleiman M, Protopopov M, Yeromina H, Sych I, Perekhoda L. The use of the docking studies with the purpose of searching potential antihypertensive drugs. Res J Pharm Technol. 2019; 12(10): 4889-94.
[31] Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017; 7: 44735.
[32] Cai F, Luis M, Lin X, Wang M, Cai L, Cen C, Biskup E. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment. Mol Clin Oncol. 2019; 11(1):15-23.
[33] Finiuk NS, Ostapiuk YuV, Hreniukh VP, Shalai YaR, Matiychuk VS, Obushak MD, Stoika RS, Babsky AM. Evaluation of antiproliferative activity of pyrazolothiazolopyrimidine derivatives. Ukr Biochem J. 2018; 90(2):25-32.
[34] Sharma PC, Bansal KK, Sharma A, Sharma D, Deep A. Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur J Med Chem. 2020; 188:112016.
[35] Hawtin RE, Stockett DE, Byl JAW, McDowell RS, Tan N, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA. Voreloxin Is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE. 2010; 5(4):e10186.
[36] Finiuk N, Klyuchivska O, Ivasechko I, Hreniukh V, Ostapiuk Y, Shalai Y, Panchuk R, Matiychuk V, Obushak M, Stoika R, Babsky A. Proapoptotic effects of novel thiazole derivative on human glioma cells. Anticancer Drugs. 2019; 30(1):27-37.
[37] Othman IMM, Alamshany ZM, Tashkandi NY, Gad-Elkareem MAM, Abd El-Karim SS, Nossier ES. Synthesis and biological evaluation of new derivatives of thieno-thiazole and dihydrothiazolo-thiazole scaffolds integrated with a pyrazoline nucleus as anticancer and multi-targeting kinase inhibitors. RSC Adv. 2021; 12(1):561-577.